BridgeBio Pharma (BBIO) vs BioMarin Pharmaceutical (BMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
BridgeBio Pharma (BBIO) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 22.6% versus a gain of 0.9%. Over five years, BBIO leads with a +38.6% price change compared with -27.3% for BMRN. BridgeBio Pharma is the larger company by market cap ($13.00 billion vs $10.69 billion), about 1.2 times the size.
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (8.3x vs 2420.8x for BridgeBio Pharma). BioMarin Pharmaceutical converts more of its revenue into profit, with a net margin of 10.8% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | BMRN |
|---|---|---|
| Share price | $66.50 | $55.20 |
| Market cap | $13.00B | $10.69B |
| 1-day change | -0.69% | -1.81% |
| YTD return | -13.06% | -7.12% |
| 1-year return | +22.65% | +0.91% |
| 5-year return | +38.60% | -27.26% |
| P/E ratio (TTM) | — | 149.19 |
| Forward P/E | — | 8.34 |
| EPS (TTM) | $-3.56 | $0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | $3.22B |
| Revenue growth (YoY) | +126.26% | +12.87% |
| Net income (latest FY) | $-732.94M | $348.90M |
| Gross margin | 95.82% | 77.73% |
| Operating margin | -104.25% | 12.71% |
| Net margin | -145.98% | 10.83% |
| 52-week high | $93.42 | $70.98 |
| 52-week low | $52.75 | $49.26 |
| Distance from 52-week high | -28.81% | -22.23% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +63.98% | +65.98% |
| Average volume | 2.75M | 2.00M |
| Shares outstanding | 195.49M | 193.57M |
| Employees | 999 | 3,221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BBIO has outperformed BMRN by 21.7 percentage points over the past year.
- BioMarin Pharmaceutical is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +12.87%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
BBIO vs BMRN FAQ
Which is bigger, BridgeBio Pharma or BioMarin Pharmaceutical?
BridgeBio Pharma (BBIO) is larger, with a market capitalization of $13.00B compared with $10.69B for BioMarin Pharmaceutical (BMRN).
Which stock has performed better over the past year, BBIO or BMRN?
BBIO returned +22.65% over the past 12 months, compared with +0.91% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and BioMarin Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.